English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Aims Obesity is becoming an important health problem as its prevalence is increasing. Obesity is also a factor that causes an increase in chronic kidney disease (CKD) cases by facilitating the development of diabetes and hypertension, which leads to CKD, and by a direct effect on the kidney and endocrine mechanism. Obesity is generally defined by body mass index (BMI), which is not a good indicator for visceral adipose tissue (VAT), as visceral fat has been shown to be more metabolically active. A new method called the visceral adiposity index (VAI) has been developed, which is considered to be an indicator for the metabolic function of VAT. Previous studies have confirmed the association between the VAI and CKD prevalence. In this study, we attempted to investigate the association between estimated glomerular filtration rate (eGFR) decline and visceral adiposity. Method Data were collected from 129 patients aged 18-80 years with stage 2-5 CKD and not on dialysis; these patients were followed up in the Nephrology Department of Usak University Hospital between December 2017 and November 2018. Results Of 129 patients with stage 2-5 CKD enrolled in this study, 64 (40.6%) were females and 66 (59.4%) were males. The mean age was 66.8 (35-80 years). The mean VAI values of patients were 2.86±1.63, and the mean eGFR decline was -12.8±19.0 ml/min/1.73m2. No correlation was observed between the VAI values and decline in eGFR in 1 year. Patients with DM had statistically significant higher eGFR decline (p=0.04) and higher VAI values (p=0.03). Conclusion The VAI, which is used to assess the metabolic function of VAT, was not associated with the eGFR decline in 1 year for patients with stage 2-5 CKD.

P0749THE ASSOCIATION OF VISCERAL ADIPOSITY INDEX WITH PROGRESSION OF CHRONIC KIDNEY DISEASE